Aripiprazole in anorexia nervosa and low‐weight bulimia nervosa: Case reports

Trunko, Mary Ellen; Schwartz, Terry Ann; Duvvuri, Vikas; Kaye, Walter H.

doi:10.1002/eat.20807

Cited by 49 publications

(44 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, stimulants such as methylphenidate or the antidepressant bupropion frequently affect food intake and promote weight loss (Anderson et al, 2002;Goldfield et al, 2007). In AN, small studies using the dopamine D2 antagonist haloperidol or the dopamine D2 partial agonist aripiprazole suggested beneficial effects on core symptoms of AN (Cassano et al, 2003;Trunko et al, 2011). Importantly, the stimulant amphetamine increased, whereas haloperidol decreased brain response in a human temporal difference model paradigm (Menon et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Anorexia Nervosa and Obesity are Associated with Opposite Brain Reward Response

Frank

Reynolds

Shott

et al. 2012

Neuropsychopharmacol

280

255

View full text Add to dashboard Cite

Anorexia nervosa (AN) is a severe psychiatric disorder associated with food avoidance and malnutrition. In this study, we wanted to test whether we would find brain reward alterations in AN, compared with individuals with normal or increased body weight. We studied 21 underweight, restricting-type AN (age M 22.5, SD 5.8 years), 19 obese (age M 27.1, SD 6.7 years), and 23 healthy control women (age M 24.8, SD 5.6 years), using blood oxygen level-dependent functional magnetic resonance brain imaging together with a rewardconditioning task. This paradigm involves learning the association between conditioned visual stimuli and unconditioned taste stimuli, as well as the unexpected violation of those learned associations. The task has been associated with activation of brain dopamine reward circuits, and it allows the comparison of actual brain response with expected brain activation based on established neuronal models. A group-by-task condition analysis (family-wise-error-corrected Po0.05) indicated that the orbitofrontal cortex differentiated all three groups. The dopamine model reward-learning signal distinguished groups in the anteroventral striatum, insula, and prefrontal cortex (Po0.001, 25 voxel cluster threshold), with brain responses that were greater in the AN group, but lesser in the obese group, compared with controls. These results suggest that brain reward circuits are more responsive to food stimuli in AN, but less responsive in obese women. The mechanism for this association is uncertain, but these brain reward response patterns could be biomarkers for the respective weight state.

show abstract

Section: Discussionmentioning

confidence: 99%

Anorexia Nervosa and Obesity are Associated with Opposite Brain Reward Response

Frank

Reynolds

Shott

et al. 2012

Neuropsychopharmacol

280

255

View full text Add to dashboard Cite

show abstract

“…SGAs may help increase insight and willingness to engage in treatment and decrease the negative cognitive processes related to food, body-image, and weight-gain. Previous case studies of adolescents treated with SGAs have shown decreased obsessional thinking, agitation, and body image concerns (McKnight & Park, 2010;Trunko et al, 2011;Flament, et al, 2012;Dennis et al, 2006). In an activity-based anorexia model in mice, olanzapine was found to significantly decrease food-related anticipatory activity, indicating that olanzapine may help reduce anxious behaviors related to AN (Klenotich et al, 2012).…”

Section: Psychological Considerations In Future Sga Researchmentioning

confidence: 90%

Anorexia Nervosa and Antipsychotics: How to Apply Research Findings to the Adolescent Population

Burton¹,

Robb²

2012

Child and Adolescent Psychopharmacology News

View full text Add to dashboard Cite

“…1-5 mg/d olanzapine, 100-400 mg/d quetiapine) were commonly used. There is also one case report supporting the use of aripipazole in three patients with bulimia nervosa as well as eight with anorexia nervosa (Trunko et al 2010). In this series, the three patients with bulimia nervosa had or previously had low weight.…”

Section: Antipsychotic Medicationsmentioning

confidence: 92%

Clinical psychopharmacology of eating disorders: a research update

Hay

Claudino

2011

Int. J. Neuropsychopharm.

112

View full text Add to dashboard Cite

The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.

show abstract

Aripiprazole in anorexia nervosa and low‐weight bulimia nervosa: Case reports

Abstract: In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN.

Cited by 49 publications

References 84 publications

Anorexia Nervosa and Obesity are Associated with Opposite Brain Reward Response

Anorexia Nervosa and Obesity are Associated with Opposite Brain Reward Response

Anorexia Nervosa and Antipsychotics: How to Apply Research Findings to the Adolescent Population

Clinical psychopharmacology of eating disorders: a research update

Contact Info

Product

Resources

About